Dulcey, L.; Theran, J.; Blanco, E.; Ciliberti, M.P.; Gutierrez, L.N.; Herran Fonseca, C.; Martinez, J. Thrombosis of Transverse Cerebral Venous Sinus Secondary to Vaccine ChAdOx1-S (Recombinant) First Report in Southamerica. Preprints2023, 2023030402. https://doi.org/10.20944/preprints202303.0402.v1
APA Style
Dulcey, L., Theran, J., Blanco, E., Ciliberti, M.P., Gutierrez, L.N., Herran Fonseca, C., & Martinez, J. (2023). Thrombosis of Transverse Cerebral Venous Sinus Secondary to Vaccine ChAdOx1-S (Recombinant) First Report in Southamerica. Preprints. https://doi.org/10.20944/preprints202303.0402.v1
Chicago/Turabian Style
Dulcey, L., Catalina Herran Fonseca and Juan Martinez. 2023 "Thrombosis of Transverse Cerebral Venous Sinus Secondary to Vaccine ChAdOx1-S (Recombinant) First Report in Southamerica" Preprints. https://doi.org/10.20944/preprints202303.0402.v1
Abstract
Introduction: Adverse events related to vaccines are reactions that can lead to serious complications, in the present that we live at the publication of this article with the need to generate high rates of vaccination have been presented in the case of vaccine agents against COVID-19 adverse events, with thrombotic events being the most important. Case Presentation: This is a 37-year-old female patient who presents 11 days after ChAdOx1-S vaccination against COVID-19 presents with intense headache associated with symptoms of intracranial hypertension, she was initially taken to simple cranial tomography showing presence of cerebral edema and indirect signs of cerebral venous thrombosis, it is proposed to carry out cerebral angiography which showed the presence of thrombosis of both transverse venous sinuses, no hypercoagulability states were found in the laboratories, the immunological tests carried out for antiphospholipid syndrome were negative, the thrombotic event was associated with the ChAdOx1-S vaccine, later the patient was taken to thrombectomy by Neuroradiology, achieving complete channeling of both transverse venous sinuses. Conclusions: Adverse events associated with vaccination have been described with multiple vaccine agents, this component against COVID-19 is also an event to consider, knowing the pathophysiology of these events is essential to be able to reduce these risks and select the least risky agent. Despite this risk, vaccination remains the only cost-effective measure to reduce the morbidity and mortality associated with COVID-19.
Keywords
Vaccine; Coronavirus; Thrombosis; Brain
Subject
Medicine and Pharmacology, Other
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
